Despite decades of research, efforts to directly target KRAS have been challenging.
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …

Covalent inhibitors of KRASG12C have shown antitumor activity against
advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and …

Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …

The RAS genes, which include H, N, and KRAS, comprise the most frequently mutated
family of oncogenes in cancer. Mutations in KRAS–such as the G12C mutation–are found in …

KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the
treatment of solid tumors. However, when compared to KRASG12C, selective inhibition of …

Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the
development of effective targeted therapies directed against RAS has lagged behind those …

KRas is the most frequently mutated oncogene in human cancer, and even 40 years after
the initial discovery of Ras oncogenes in 1982, no approved drug directly targets Ras in Ras …

The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

Purpose: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …